{"metadata":{"kernelspec":{"language":"python","display_name":"Python 3","name":"python3"},"language_info":{"name":"python","version":"3.7.12","mimetype":"text/x-python","codemirror_mode":{"name":"ipython","version":3},"pygments_lexer":"ipython3","nbconvert_exporter":"python","file_extension":".py"}},"nbformat_minor":4,"nbformat":4,"cells":[{"cell_type":"code","source":"!pip install transformers\n!pip install SentencePiece\n!pip install pandas\n!pip install tqdm","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:35:17.521451Z","iopub.execute_input":"2023-01-31T01:35:17.522857Z","iopub.status.idle":"2023-01-31T01:35:59.623551Z","shell.execute_reply.started":"2023-01-31T01:35:17.522757Z","shell.execute_reply":"2023-01-31T01:35:59.622310Z"},"trusted":true},"execution_count":1,"outputs":[{"name":"stdout","text":"Requirement already satisfied: transformers in /opt/conda/lib/python3.7/site-packages (4.20.1)\nRequirement already satisfied: huggingface-hub<1.0,>=0.1.0 in /opt/conda/lib/python3.7/site-packages (from transformers) (0.10.1)\nRequirement already satisfied: tqdm>=4.27 in /opt/conda/lib/python3.7/site-packages (from transformers) (4.64.0)\nRequirement already satisfied: regex!=2019.12.17 in /opt/conda/lib/python3.7/site-packages (from transformers) (2021.11.10)\nRequirement already satisfied: importlib-metadata in /opt/conda/lib/python3.7/site-packages (from transformers) (6.0.0)\nRequirement already satisfied: packaging>=20.0 in /opt/conda/lib/python3.7/site-packages (from transformers) (23.0)\nRequirement already satisfied: requests in /opt/conda/lib/python3.7/site-packages (from transformers) (2.28.1)\nRequirement already satisfied: tokenizers!=0.11.3,<0.13,>=0.11.1 in /opt/conda/lib/python3.7/site-packages (from transformers) (0.12.1)\nRequirement already satisfied: numpy>=1.17 in /opt/conda/lib/python3.7/site-packages (from transformers) (1.21.6)\nRequirement already satisfied: filelock in /opt/conda/lib/python3.7/site-packages (from transformers) (3.7.1)\nRequirement already satisfied: pyyaml>=5.1 in /opt/conda/lib/python3.7/site-packages (from transformers) (6.0)\nRequirement already satisfied: typing-extensions>=3.7.4.3 in /opt/conda/lib/python3.7/site-packages (from huggingface-hub<1.0,>=0.1.0->transformers) (4.1.1)\nRequirement already satisfied: zipp>=0.5 in /opt/conda/lib/python3.7/site-packages (from importlib-metadata->transformers) (3.8.0)\nRequirement already satisfied: idna<4,>=2.5 in /opt/conda/lib/python3.7/site-packages (from requests->transformers) (3.3)\nRequirement already satisfied: charset-normalizer<3,>=2 in /opt/conda/lib/python3.7/site-packages (from requests->transformers) (2.1.0)\nRequirement already satisfied: urllib3<1.27,>=1.21.1 in /opt/conda/lib/python3.7/site-packages (from requests->transformers) (1.26.14)\nRequirement already satisfied: certifi>=2017.4.17 in /opt/conda/lib/python3.7/site-packages (from requests->transformers) (2022.12.7)\n\u001b[33mWARNING: Running pip as the 'root' user can result in broken permissions and conflicting behaviour with the system package manager. It is recommended to use a virtual environment instead: https://pip.pypa.io/warnings/venv\u001b[0m\u001b[33m\n\u001b[0mRequirement already satisfied: SentencePiece in /opt/conda/lib/python3.7/site-packages (0.1.97)\n\u001b[33mWARNING: Running pip as the 'root' user can result in broken permissions and conflicting behaviour with the system package manager. It is recommended to use a virtual environment instead: https://pip.pypa.io/warnings/venv\u001b[0m\u001b[33m\n\u001b[0mRequirement already satisfied: pandas in /opt/conda/lib/python3.7/site-packages (1.3.5)\nRequirement already satisfied: python-dateutil>=2.7.3 in /opt/conda/lib/python3.7/site-packages (from pandas) (2.8.2)\nRequirement already satisfied: pytz>=2017.3 in /opt/conda/lib/python3.7/site-packages (from pandas) (2022.1)\nRequirement already satisfied: numpy>=1.17.3 in /opt/conda/lib/python3.7/site-packages (from pandas) (1.21.6)\nRequirement already satisfied: six>=1.5 in /opt/conda/lib/python3.7/site-packages (from python-dateutil>=2.7.3->pandas) (1.15.0)\n\u001b[33mWARNING: Running pip as the 'root' user can result in broken permissions and conflicting behaviour with the system package manager. It is recommended to use a virtual environment instead: https://pip.pypa.io/warnings/venv\u001b[0m\u001b[33m\n\u001b[0mRequirement already satisfied: tqdm in /opt/conda/lib/python3.7/site-packages (4.64.0)\n\u001b[33mWARNING: Running pip as the 'root' user can result in broken permissions and conflicting behaviour with the system package manager. It is recommended to use a virtual environment instead: https://pip.pypa.io/warnings/venv\u001b[0m\u001b[33m\n\u001b[0m","output_type":"stream"}]},{"cell_type":"code","source":"#DEFINE LANGUAGES\nlanguage1 = \"en\"\nlanguage2 = \"ja\"\nfile = \"retrieval\"","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:35:59.626192Z","iopub.execute_input":"2023-01-31T01:35:59.626603Z","iopub.status.idle":"2023-01-31T01:35:59.632338Z","shell.execute_reply.started":"2023-01-31T01:35:59.626560Z","shell.execute_reply":"2023-01-31T01:35:59.631393Z"},"trusted":true},"execution_count":2,"outputs":[]},{"cell_type":"code","source":"#COVID\nimport pandas as pd\nimport json\n\n#retrieval\ninput_json = f\"../input/cpgqa-dataset/cpgQA-{file}_train.json\"\nwith open(input_json, \"r\", encoding = \"utf-8\") as json_file:\n    objs = json.load(json_file)\n\nquestions = []\nfor i in range(len(objs)):\n        question = objs[i][\"question\"]\n        questions.append(question)\nquestions","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:35:59.634002Z","iopub.execute_input":"2023-01-31T01:35:59.634755Z","iopub.status.idle":"2023-01-31T01:35:59.698497Z","shell.execute_reply.started":"2023-01-31T01:35:59.634710Z","shell.execute_reply":"2023-01-31T01:35:59.697417Z"},"trusted":true},"execution_count":3,"outputs":[{"execution_count":3,"output_type":"execute_result","data":{"text/plain":"['what are the components of biopsychosocial assessment?',\n 'alternatives to opioids are recommended for what?',\n 'what includes prior medical records?',\n 'in a sample of non-treatment-seeking members of the military who were interviewed within three months of returning from afghanistan, how many reported using opioids?',\n 'how much to take from days 11 to 20, when using morphine sr 15 mg tablets?',\n 'what therapies are preferred for chronic pain?',\n 'what should be done at every phase of treatment?',\n 'what can cause a toxidrome?',\n 'which conditions can complicate pain management?',\n 'what to do if there are issues with the veteran obtaining outside prescriptions during the taper?',\n 'which interventions are safe and have not been shown to increase morbidity or mortality?',\n 'what to do if the patient is not willing to engage in sud therapy?',\n 'what are the necessary risk mitigation strategies?',\n 'why should an optimal approach to care should include a robust,  signature informed consent process?',\n 'what is not the intention of this guideline?',\n 'among patients on ot, a prevalence of self inflicted injuries was significantly higher among which patients?',\n 'under which circumstances risks of opioid therapy outweigh benefits?',\n 'what to do when patient requests to discontinue therapy?',\n 'what does the otrr do?',\n 'veterans receiving both opioids and benzodiazepines were at an increased risk of what?',\n 'since when has there been growing recognition of an opioid misuse epidemic, including among america’s veterans?',\n 'what is recommended when pharmacologic therapies are used?',\n 'in 2012, how many opioid prescriptions were written by healthcare providers for every 100 persons in the u.s.?',\n 'what were the goals of president’s national drug control strategy in 2010?',\n 'is there any evidence that take-home naloxone programs are effective in improving overdose survival and decreasing mortality, with a low rate of adverse events?',\n 'what is the stance regarding the concurrent use of benzodiazepines and opioids?',\n 'what were associated with decreased risk of suicide attempt?',\n 'what are non-opioid treatments for chronic pain?',\n 'which one is a dangerous or fatal cardiac arrhythmia?',\n 'when did the cdc released its guideline for prescribing opioids for chronic pain? ',\n 'should you prescribe the highest or lowest effective dose when starting therapy?',\n 'what did the cdc guideline development process include? ',\n 'what does the national drug control strategy advocate?',\n 'what kinds of pain education groups should be offered to veterans?',\n 'what are included in the strategies and their frequency?',\n 'when is it recommended more frequent monitoring for adverse events?',\n 'what is module b about?',\n 'what indicate that developing brains (age <30 years) are at increased risk of abnormalities and  addiction when exposed to substance use early in life?',\n 'which factor can help identify non-adherence to a comprehensive pain care plan?',\n 'what are some examples of synthetic opioids?',\n 'what is needed when there are progressive changes in bowel or bladder function?',\n 'what unique properties does methadone have?',\n 'what does increase the risk of fatal or non-fatal opioid overdose 2-10 fold across opioid dose ranges?',\n 'when was the 2015 national drug control strategy released?',\n 'what are the risk factors with the greatest impact on the development of opioid-related adverse events?',\n 'when did chronic pain management became synonymous with lot?',\n 'what are the risks of continuing opioid therapy?',\n 'which health issue has been identified as an epidemic?',\n 'what must vha providers follow when providing lot for patients with non-cancer pain?',\n 'where can more information be found on ptsd?',\n 'when to follow up?',\n 'which factors require immediate attention and possible discontinuation?',\n 'what is the first-line treatment option for autonomic symptoms?',\n 'what do opioids do to the bowel?',\n 'what to do when veteran feels supported and is adjusting to the dose reduction?',\n 'at what range of dose the risks for overdose and death significantly increase?',\n 'during the first month in the slower taper what does consist of 16% reduction of morphine sr 90 mg q8h = 270 medd?',\n 'what is recommended for patients currently on long-term opioid therapy with evidence of untreated substance use disorder?',\n 'what is the clinical practice guideline based on?',\n 'what was associated with 28 times increased  odds of therapeutic opioid addiction compared to patients with cncp without a lifetime history of sud?',\n 'which groups had the highest prevalence of opioid use?',\n 'what is torsades de pointes?',\n 'which one is the most common taper?',\n 'what does increase the aor of  overdose?',\n 'what to do if the patient does not demonstrate signs or symptoms of sud?',\n 'what is not the intention of the guideline?',\n 'when should non-opioids be recommended over opioids?',\n 'what to do when patients are displaying other aberrant behaviors during the taper?',\n 'what does the osi requirements include?',\n 'what should be performed with caution and within a team environment when possible?',\n 'what to do if there is no clinically meaningful improvement in function in the absence of significant risk factors?',\n 'what is osi?',\n 'what should be weighed heavily in the risk-benefit determination for initiating lot?',\n 'who facilitates the distribution of naloxone for the reversal?',\n 'how long does the faster taper take?',\n 'what does not guarantee coverage of civilian sector care?',\n 'what does the osi use to identify patients who may be  high-risk for adverse outcomes with use of opioids?',\n 'which one is the strongest predictor of developing oud among opioid dose and duration of ot?',\n 'how many adults in the u.s. experience chronic pain?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on month 1, what dose should be taken on month six of the slower opioid tapering?',\n 'what are the requirements in the policy issued by the vha to further promote safety and patient centered care?',\n 'what to do if prior medical records are not available for review?',\n 'why must the clinician carefully weigh harms and benefits and educate the patient as well as his or her family or caregiver prior to proceeding with treatment?',\n 'which factors can increase the risks of ot?',\n 'which step should be taken to address the problem of opioid-related overdose epidemic?',\n 'in which instances more rapid tapers may be required?',\n 'when to consider consultation with local risk management and/or counsel?',\n 'what to do when there are concerns related to an increased risk of sud?',\n 'how much opioid to reduce in the slower taper?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on week 1, what dose should be taken on week three of the faster opioid tapering?',\n 'which behaviors can be characterized as unsafe?',\n 'what does the u.s. department of health and human services (hhs) national pain strategy  (march 2016) recommend?',\n 'which approach to follow when initiating ot?',\n 'what should be avoided unless required for immediate safety concerns?',\n 'which areas in the cns are involved in the chronic pain?',\n 'what is the stance regarding alternatives to opioid therapy such as self-management strategies and other non-pharmacological treatments?',\n 'what is the alternative treatment option for autonomic symptoms using gabapentin?',\n 'what strategies will help in the transition?',\n 'what can happen with a strategy of escalating dose during ot?',\n 'at what dosage does the risk increase even further?',\n 'what to do before initiating ot?',\n 'why are ecgs highly advised before and after initiating methadone?',\n 'in operation enduring freedom/operation iraqi freedom (oef/oif) veterans, chronic pain was associated with what?',\n 'what is an example of high-risk behaviors?',\n 'what was the outcome of the survey of patients prescribed opioids for chronic non-cancer pain and their family members?',\n 'what to do if the veteran is suicidal, have high suicide risk or actively suicidal?',\n 'what are some examples of opioid agonist medications?',\n 'what contributed to strong recommendations in multiple instances?',\n 'what can be the reasons for the reluctance in further dose reductions?',\n 'what is the rate of a gradual taper?',\n 'what can be caused by rapid taper?',\n 'what is module c about?',\n 'how to perform tapering of benzodiazepines?',\n 'what to follow up or review before starting opioid therapy?',\n 'what to use for more frequent follow-up?',\n 'what does recommend against benzodiazepines for the prevention of ptsd?',\n 'what methodology was used in developing the 2017 cpg?',\n 'in addition to non-pharmacological therapies, what should be tried and optimized before consideration of opioid medications?',\n 'among patients  being treated by the vha system that received opioids, what was significantly associated with opioid-related toxicity/overdose compared to no history of  depression?',\n 'when do the risks for opioid use disorder start?',\n 'what to do if there is a clinically meaningful improvement in function in the absence of significant risk factors?',\n 'when was the department of veterans affairs (va) and department of defense (dod) evidence-based practice work group (ebpwg) was established and first chartered?',\n 'what is not first-line or routine therapy for chronic pain management?',\n 'what are cpgs?',\n 'what is the most common method of abuse?',\n 'what to do when there are concerns related to an increased risk of substance use disorder?',\n 'what does increase the risk of acute post-operative ot progressing into lot?',\n 'what may gradual benzodiazepine taper result in?',\n 'what does the work group recognize?',\n 'what was the basis for the clinical practice guideline for management of opioid therapy for chronic pain published in 2010?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month nine of the slowest opioid tapering?',\n 'what is ot?',\n 'what to do when veteran is safe?',\n 'who will have co-occurring medical conditions?',\n 'since when has there been a significant increment of opioid-related morbidity, mortality, overdose death, and sud treatment admissions?',\n 'what was increasing at an alarming rate until recently?',\n 'what is a life-saving measure following opioid overdose?',\n 'what does carry a significant risk for oud, overdose, and death, especially among patients with untreated  sud?',\n 'what was the national academy of medicine formerly known as?',\n 'what to do if a patient is showing signs of aberrant behavior?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on week 1, what dose should be taken on week seven of the faster opioid tapering?',\n 'what are the odds of suicidal ideation within the past 12 months in those with bipolar disorder compared to those with no bipolar disorder?',\n 'who have an added great risk for oud and overdose?',\n 'what to do at follow-up visits?',\n 'what to do with the increment of opioid dosage and risk?',\n 'what should the clinicians ask the patient?',\n 'what is the stance regarding the long-term opioid therapy for pain in patients with untreated substance use disorder?',\n 'in 2012, how many benzodiazepine prescriptions were written by healthcare providers for every 100 persons in the u.s.?',\n 'who will need to determine whether a telephone or in-clinic appointment is appropriate based on the risk category of the veteran?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day six of the rapid opioid tapering?',\n 'how to use a cpg?',\n 'what are some examples of high-risk or dangerous behavior?',\n 'what is module d for?',\n 'who report psychological complaints more often?',\n 'in which cases it is essential to involve behavioral health to assess, monitor, and treat a patient who becomes destabilized as a result of a medically appropriate decision to taper or cease lot?',\n 'what should be commensurate with risk factors?',\n 'which factors can raise concerns related to an increased risk of substance use disorder?',\n 'what was the increment of the prevalence of opioid prescriptions among veterans from fiscal years 2004 to 2012?',\n 'further research is needed for what?',\n 'during the first week in the faster taper what does consist of 16% reduction of morphine sr 90 mg q8h = 270 medd?',\n 'how long does it take for prolonged withdrawal symptoms to appear?',\n 'what is essential to do when a patient becomes destabilized as a result of a medically appropriate decision to taper or cease lot?',\n 'based on which factors providers will need to determine whether a telephone or in-clinic appointment is appropriate?',\n 'what kind of care is recommended that addresses pain, substance use disorders, and/or mental health problems for patients presenting with high risk and/or aberrant behavior?',\n 'when is a short duration recommended?',\n 'compared to whom, patients 30-39  years old had roughly half the risk of developing oud or overdose?',\n 'what is this ot cpg designed to do?',\n 'what to consider for patients currently on long-term opioid therapy and benzodiazepines?',\n 'what to do if the patient is willing to engage in a comprehensive pain care plan?',\n 'during the first day in the rapid taper what does consist of 33% reduction of morphine sr 90 mg q8h = 270 medd?',\n 'younger patients are at a higher risk of what?',\n 'which government agencies launched initiatives to improve the study and treatment of pain and  adverse events associated with opioid analgesics?',\n 'what to do if patient is fearful or anxious about taper and ability to function on lower dose or without opioids?',\n 'what to follow up or review during opioid therapy?',\n 'when formulating an opioid taper plan, what can be the initial goal?',\n 'what is the estimation of the lifetime prevalence for moderate symptoms of oud among patients receiving long-term opioid therapy?',\n 'prior to any changes being made in opioid prescribing, a discussion should occur between whom?',\n 'what happens in the biomedical model of pain care?',\n 'lot is an ineffective treatment modality for patients with what kind of headaches?',\n 'what to do if adding ot to comprehensive pain therapy is indicated at this time?',\n 'what are the benefits of continuing opioid therapy?',\n 'what do autonomic symptoms include?',\n 'what does the algorithm include?',\n 'what to do if the treatments are not effective in managing pain and optimizing function?',\n 'when will the variations in practice inevitably and appropriately occur?',\n 'in a study of veterans with chronic pain who had been on opioids for at least 90 days, how many continued to use opioids after completion of the 3.5 year follow-up period?',\n 'what should be approached with extreme caution and warrants specialty consultation?',\n 'what is the stance regarding the initiation of long-term opioid therapy for chronic pain?',\n 'what is the alternative management strategy that is beneficial for patients receiving opioid analgesics who do not meet dsm-5 criteria for oud?',\n 'what are some examples of psychological therapies?',\n 'returning unused opioid medications has been explored as a strategy for what?',\n 'what is recommended if take-home opioids are prescribed?',\n 'which medical comorbidities can increase risk during opioid therapy?',\n 'where to follow up with the veteran during the faster taper?',\n 'what should be offered for patients with oud?',\n 'why is it important to consider patients’ values and concerns, address misconceptions, express empathy, and fully explain to patients with one or more risk factors that they may not benefit from, and may even be harmed by, treatment with ot?',\n 'which efforts led to an unprecedented increase in opioid prescribing for chronic non-terminal pain?',\n 'which long-acting agents can be used for acute pain?',\n 'in a study of patients on opioids, who had 2.9 times the odds of suicidal ideation within the past 12 months as well as 3.2  times the odds of a lifetime suicide attempt compared to those with no bipolar disorder?',\n 'how was ot used prior to 1980s?',\n 'what specific information can this guideline provide to guide a patient encounter?',\n 'what was the statistics of the events related to oud or prescription drug overdose in 2014?',\n 'what needs to be addressed for patients with chronic pain who develop oud from opioid analgesic therapy?',\n 'what to do if a patient is taking more than their prescribed dosage of opioids?',\n 'what may be considered after stopping rapid tapering after day 11?',\n 'which was the dominating period of the biomedical model of pain care?',\n 'what are the risks associated with a fentanyl transdermal delivery system (or patch)?',\n 'which tapers may be required in certain instances like situations where the risks of continuing the opioid outweigh the risks of a rapid taper?',\n 'the use of a cpg must always be considered as what?',\n 'what is the first-line treatment for oud?',\n 'what to monitor for when considering an opioid taper?',\n 'what does the storm tool do?',\n 'what is ebpwg?',\n 'what are some examples of synthetic opioids?',\n 'this cpg is based on what?',\n 'what is the strength of this cpg?',\n 'how can the use of opioids affect patients with impaired bowel motility?',\n 'how do the risks for opioid use disorder increase?',\n 'what to do if suicide risk is high in patients?',\n 'when should clinicians obtain udt?',\n 'what warrants an urgent evaluation during opioid therapy?',\n 'who does assess the critical information needed at the major decision points in the clinical process?',\n 'for whom assessment for opioid use disorder is recommended?',\n 'on which basis the frequency of follow-ups with a patient on ot should be considered?',\n 'how long does it take to lose tolerance?',\n 'what kind of intervention has been  shown to be more effective than usual care in improving pain and disability?',\n 'what should the clinicians do for patients who decline mat for oud?',\n 'name the concerning factors regarding the use of ot prior to 1980s.',\n 'how can a health care system use the cpg?',\n 'in which topics the goals of the osi is related to?',\n 'when are non-opioids recommended over opioids?',\n 'when the risks of continuing the opioid outweigh the risks of a rapid taper, which tapers may be required?',\n 'when to consider tapering opioids to taper and discontinue?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on week 1, what dose should be taken on week two of the faster opioid tapering?',\n 'for whom to evaluate for tapering to reduced dose or to discontinuation?',\n 'what is reported more often by the patients with chronic pain than patients without chronic pain?',\n 'how much opioid to reduce in the slowest taper?',\n 'what includes personal history of sud?',\n 'what is the alternative treatment option for autonomic symptoms using baclofen?',\n 'what are some examples of poorly localized symptoms?',\n 'what are the causes of chronic pain?',\n 'what is the alternative treatment option for autonomic symptoms using tizanidine?',\n 'what maybe included in interdisciplinary services?',\n 'what can signal an emerging sud as well as  diversion?',\n 'should the opioid-naive individuals be prescribed long-acting opioids?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on week 1, what dose should be taken on week six of the faster opioid tapering?',\n 'what to do if risks do not outweigh benefits of continuing ot?',\n 'when to follow-up after each change in dosage?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day eleven of the rapid opioid tapering?',\n 'is there any evidence that intensification of monitoring helps mitigate the risk of suicide among patients on lot?',\n 'what may help determine earlier in the course of treatment which patients are most likely to  benefit from a specific non-pharmacologic therapy or non opioid pharmacologic therapies alone or as part of a multimodal approach?',\n 'what are the characteristics of higher risk medication?',\n 'what benefits are recommended to be evaluated at least every 3 months?',\n 'what can allow the patient time to acquire new skills for management of pain and emotional distress while allowing for neurobiological equilibration?',\n 'how have otas been described in the 2010 ot cpg?',\n 'what is recommended for mild-to-moderate acute pain?',\n 'what to do if an sud is not identified?',\n 'what to do if there is presence of combined sedating medication that increases risk of adverse events (e.g., benzodiazepine)?',\n 'how often the urine drug testing needs to be performed?',\n 'what is needed to ascertain whether said formulations differ across clinical outcomes such as pain, function,  and adverse events?  ',\n 'if a veteran is currently taking morphine sr 60 mg, 1 tablet every 8 hours and the goal is to reduce the dose of morphine to sr 30 mg every 8 hours using a slow taper, how to reduce opioid dose?',\n 'which pain may lead to poorly localized symptoms?',\n 'what is the stance regarding prescribing long-acting opioids for acute pain?',\n 'where to follow up with the veteran during the slowest taper?',\n 'what was highest for individuals on lot for chronic pain (without anxiety or ptsd) who also received  concurrent long-term benzodiazepine therapy?',\n 'at what dose do the risks for overdose and death increase?',\n 'what does interdisciplinary care do?',\n 'what is cns?',\n 'what to consider for patients currently on long-term opioid therapy and benzodiazepines?',\n 'what are the treatment options for anxiety, dysphoria, lacrimation, and rhinorrhea?',\n 'to which modalities should the patient have access?',\n 'what to consider for patients who are actively engaged in skills training?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day four of the rapid opioid tapering?',\n 'how much to take from days 1 to 10, when using morphine sr 15 mg tablets?',\n 'what is an example of medication that can increase risk during opioid therapy, if used concomitantly?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month two of the slowest opioid tapering?',\n 'self-management strategies are recommended as alternatives to what?',\n 'which electronic tools are currently used in the va?',\n 'why should the providers discuss with patients that progression from acute to long-term ot is associated with little evidence  for sustained analgesic efficacy but a substantial increase in risk for oud?',\n 'what should be commensurate with risk factors?',\n 'what does opioid agonist treatment involve?',\n 'what would happen if there were a more frequent follow-up of patients on lot?',\n 'how to characterize pain as a symptom?',\n 'what treatment is recommended to offer for opioid use disorder to patients with chronic pain and opioid use disorder?',\n 'who are provided opioid therapy treatment?',\n 'with whom to follow up during opioid taper?',\n 'what is lot?',\n 'what to assess for patients already on ot?',\n 'why is frequent follow-up needed?',\n 'how long does the rapid taper take?',\n 'what to document in the veteran’s medical record?',\n 'from 2000 through 2010, what was the increment of the proportion of pain visits during which non-opioid pharmacologic therapies were prescribed?',\n 'what can be signalled by frequent requests for early refills required to control pain?',\n 'what should providers carefully rule out and avoid?',\n 'what to consider to reduce withdrawal symptoms during the taper?',\n 'what can have potential adverse outcomes in patients who do not have depression?',\n 'what should be arranged for patients with oud?',\n 'who does recommend a biopsychosocial approach to pain care that is multimodal and interdisciplinary?',\n 'who are the target population for the va/dod ot cpg?',\n 'what are the guidelines based upon?',\n 'when to avoid diphenhydramine?',\n 'among the veterans, who were less likely to continue their opioid use?',\n 'what to do when there is non-adherence to the treatment plan or unsafe behaviors?',\n 'who recommends at least quarterly checks of the state database system?',\n 'what has accumulated growing attention from federal and local officials as well as other policymakers?',\n 'what are associated with a higher incidence of ptsd symptoms?',\n 'how long does it take to complete slower tapers?',\n 'when the patient is willing to engage in a comprehensive pain care plan, what to educate the patient and family about?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day five of the rapid opioid tapering?',\n 'which can help reduce withdrawal symptoms?',\n 'what is one of the most common chronic medical conditions in the u.s.?',\n 'what is an ineffective treatment modality for patients with migraine headaches (with or without aura), tension-type headaches, occipital neuralgia, or myofascial pain?',\n 'what is the relationship between opioid dosage and risks of opioid overdose?',\n 'when is assessing suicide risk and intervening recommended?',\n 'what do psychological therapies help?',\n 'how much opioid to reduce in the faster taper?',\n 'patients in the 45-64 year age group were significantly less likely to have an aberrant udt (detection of a non-prescribed opioid, non-prescribed  benzodiazepine, illicit drug, or tetrahydrocannabinol [thc]) in comparison to whom?',\n 'if the patients under opioid taper pna resume their original dose, they are at risk of what?',\n 'what to do if there is no concern for diversion?',\n 'what is the estimated lifetime prevalence for oud among patients receiving long-term opioid therapy?',\n 'what must be determined through individual clinical assessment?',\n 'what is an ineffective treatment modality for patients with migraine headaches (with or without aura)?',\n 'when to stop rapid tapering?',\n 'some patients with sud may disagree with what?',\n 'what to do if the factors that increase risks of ot are not present?',\n 'what is an example of bio-psycho-social model?',\n 'patients in the 45-64 and ≥65 age groups were significantly less likely than whom to  have non-detection of a prescribed opioid (indicating possible diversion)?',\n 'which factors increase overdose risk when opioids are used for acute pain?',\n 'what does significantly increase at a range of 20- 50 mg morphine equivalent daily dose?',\n 'what is considered a contraindication to initiation of ot?',\n 'how long does it take for early withdrawal symptoms to appear?',\n 'what does pdmp mean?',\n 'what is recommended for patients currently on long-term opioid therapy?',\n 'what is the stance regarding the abuse deterrent formulations for lot?',\n 'what should be individualized based upon patient characteristics and preferences?',\n 'why did the national academy of medicine issue a call for the transformation of pain care to a biopsychosocial, multimodal, interdisciplinary model?',\n 'what combinations of drugs are dangerous?',\n 'for nsaids, be cautious for which patients?',\n 'what was the first opioid used by most of the people entering sud treatment for heroin use in the 2000s?',\n 'at what dose do risks for opioid use disorder increase?',\n 'what is the stance regarding long-term opioid therapy for patients less than 30 years of age  secondary to higher risk of opioid use disorder and overdose?',\n 'what should the clinicians offer to reduce opioid risk?',\n 'what are some examples of psychological complaints made by patients with chronic pain?',\n 'what are the red flags in a patient who is taking more than their prescribed dose or showing signs of aberrant behavior?',\n 'what is recommended if take-home opioids are prescribed?',\n 'what to do when there are concerns regarding risks of tapering?',\n 'what should be offered for patients with opioid use disorder?',\n 'what to do if patient risk outweighs benefits?',\n 'how did a more cautious approach to ot for chronic non-terminal pain emerge?',\n 'what not to use to treat withdrawal symptoms?',\n 'who issued a policy requiring  standardized education and signature informed consent for all patients receiving lot for non-cancer  pain? ',\n 'what are the elements of the biopsychosocial pain interview?',\n 'when should the providers discuss with patients that progression from acute to long-term ot is associated with little evidence  for sustained analgesic efficacy but a substantial increase in risk for oud?',\n 'when to follow up with the veteran during the rapid taper?',\n 'what is the utmost concern for patients who receive ot beyond 90 days?',\n 'how many discharges in the emergency department included prescriptions for opioids?',\n 'what percentage of people entering sud treatment for heroin use started using prescription opioids as their first opioid in the 2000s?',\n 'what to do if referral/consultation for evaluation and treatment is indicated?',\n 'when to take individualized decisions about which formulation to be tapered first?',\n 'what to do if a patient is medically or psychiatrically unstable?',\n 'in a sample of non-treatment-seeking members of the military who were interviewed within three months of returning from afghanistan, how many reported chronic pain?',\n 'who should not be prescribed long-acting opioids?',\n 'which pain may produce a less localized pain?',\n 'what evidence is there to recommend psychological over physical therapies or vice versa?',\n 'what to consider while deciding when to follow up with a patient after each change in dosage or after discontinuation?',\n 'how may pauses in the slowest opioid taper help the patient?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day seven of the rapid opioid tapering?',\n 'what to do if there is an indication to taper to reduced dose or taper to discontinuation?',\n 'what does the literature say about the the benefit of lot?',\n 'why only nine key questions (kqs) were prioritized from many possible kqs?',\n 'how was an age of 30 years chosen as a clinically reasonable threshold?',\n 'why does morphine frequently cause itching?',\n 'what are motivational interviewing (mi) techniques used for?',\n 'which factors increase the risk of opioid overdose?',\n 'what are the adverse effects of lot?',\n 'continuing to prescribe the opioid without providing oud treatment may increase the risk of what?',\n 'what should be done prior to any changes being made in opioid prescribing?',\n 'why is it important that providers who suspect diversion base treatment plans on objective evidence?',\n 'who may have different needs or respond to treatment differently than individuals with chronic pain alone?',\n 'what is the purpose of opioid taper decision tool?',\n 'how was the national pain strategy published?',\n 'what does it mean by sud?',\n 'what to do if there is no presence of prescribed opioid dose>90 mg medd or combined sedating medication that increases risk of adverse events or patient non-participation in a comprehensive pain care plan or other indications for tapering? ',\n 'what is the relationship between the length of ot and opioid-related harms?',\n 'what called attention to the need for a paradigm shift in pain and its treatment protocols?',\n 'which tapers are often the most tolerable?',\n 'what is a serious risk factor for unintentional overdose death?',\n 'why non-opioid  treatments are preferred for chronic pain?',\n 'what do early symptoms include?',\n 'all patients who take opioids chronically are at risk for what?',\n 'the lowest dose of opioids is prescribed indicated by which factor?',\n 'what are some examples of complementary and integrative health (cih) interventions?',\n 'when may lot be appropriate?',\n 'what to do after educating the patient?',\n 'who may require a clinic visit over telephone follow-up?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month four of the slowest opioid tapering?',\n 'what is the treatment option for sleep disturbance?',\n 'what is the scope of this cpg?',\n 'what should be exhausted before consideration of lot?',\n 'due to the difficulty of tapering or discontinuing benzodiazepines, what should be done when considering initiating benzodiazepines for veterans with ptsd who have co-occurring chronic pain?',\n 'why is udt and confirmatory testing used as an additional method of examining for patient substance misuse and adherence to the  prescribed regimen?',\n 'how to confirm suspicions regarding drug diversion?',\n 'what is module a about?',\n 'what has been explored as a strategy to reduce the amount of opioids in  the community?',\n 'what does it mean by severe unmanageable adverse effects?',\n 'is there any study looking at opioid treatment agreements  (otas)?',\n 'what to do if there are no indications to discontinue or taper?',\n 'what is the effect of benzodiazepines in patients with ptsd?',\n 'how much has the absolute number of deaths associated with the use of opioids increased from 2013 to 2014?',\n 'when to continue opioid therapy?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month three of the slowest opioid tapering?',\n 'if take-home opioids are prescribed, what is the recommended dose of immediate-release opioids?',\n 'at what dosage there is a significant risk?',\n 'what is not recommended as an appropriate response if suicide risk is high or increases?',\n 'how to determine the acuteness of suicide risk in patients?',\n 'in patients receiving lot, who are 50% more likely to escalate to high-dose opioids and twice as likely to  experience an opioid-related death?',\n 'what to consider at the time of re-examining at a follow-up visit?',\n 'what do prolonged symptoms include?',\n 'what accompanies the illicit use of injectable opioids?',\n 'for patients who are in chronic pain and have not been on daily ot for pain for more than 3 months, which topics to consider for educating or re-educating them?',\n 'given the recognized risks of opioid therapy, what should be included in an optimal approach to care?',\n 'what is the stance regarding prescribing long-acting opioids as an as-needed medication?',\n 'what are the indications for tapering and discontinuation?',\n 'for which patients close monitoring, including engagement in substance use disorder treatment, and discontinuation of opioid therapy for pain with appropriate tapering are recommended?',\n 'what was the considerations behind the recommendations made in the cpg?',\n 'how to decide the frequency of follow-up visits?',\n 'how does the department of veterans affairs (va) and department of defense (dod) evidence-based practice work group (ebpwg) advise the “…health executive council on the use of clinical and epidemiological evidence to improve the health of the population across the veterans health administration and military health system,”?',\n 'what includes expanded care team?',\n 'what to do if the veteran is suicidal?',\n 'what kind of rationale is there to explain the the relationship between age and oud and overdose?',\n 'the use of the algorithm format as a way to represent patient management was chosen based on what?',\n 'which can help reduce withdrawal symptoms and help with pain, anxiety, and sleep?',\n 'among the veterans, who were more likely to continue their opioid use?',\n 'tapering will involve dose reduction of how much?',\n 'why did the national academy of medicine investigated and reported on the state of pain research, treatment, and  education in the u.s. in 2011?',\n 'how did ot increasingly become a mainstay for cancer and end-of-life pain?',\n 'where can the osi toolkit materials be found? ',\n 'how long does the slowest taper take?',\n 'who is responsible for evaluating the appropriateness of applying the guidelines?',\n 'compared to patients ≥65 years old, patients 18-30 years old carried how many times the odds of oud  and overdose?',\n 'what kind of risk is associated with concurrent benzodiazepine and lot use?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month six of the slowest opioid tapering?',\n 'what is recommended for patients currently on long-term opioid therapy?',\n 'what kind of opioids to use when starting therapy?',\n 'what was the leading cause of injury-related death in the u.s. in 2009?',\n 'what is one of the most disabling chronic medical conditions in the u.s.?',\n 'which medications are lethal?',\n 'for whom to consider tapering one or both benzodiazepines and opioids when risks exceed benefits and obtaining specialty consultation as appropriate?',\n 'is there any evidence that, at the facility level, patients on lot within facilities ordering more drug screens than the comparison group were associated with decreased risk of suicide attempt?',\n 'what are some examples of comprehensive pain care plan?',\n 'the recommendation against lot for patients with sud does not refer to which patients?',\n 'what is suggested to be used when opioids are used for acute pain?',\n 'what may be considered after stopping faster tapering after month 7?',\n 'what is visns?',\n 'what are the preferred treatments for chronic non-terminal pain?',\n 'it is recommended to individualize opioid tapering based on what?',\n 'who will have greater mortality?',\n 'which areas in the cns are involved in the acute and subacute pain?',\n 'what to do when an opioid allergy is present and ot is being considered?',\n 'what is the first recommendation for patients who develop oud and progress to intravenous drug use?',\n 'who had roughly half the risk of developing oud or overdose compared to subjects 18-29 years old?',\n 'what is needed when there is a history of internal malignancy that has not been re-staged?',\n 'how much dose escalation has not been shown to improve function and increase risk?',\n 'what was launched by the va as part of the osi?',\n 'what to do if risks outweigh benefits of continuing ot?',\n 'what to do if there are factors that would require immediate attention?',\n 'what is multidisciplinary biopsychosocial rehabilitation?',\n 'opioids carry a significant risk for what?',\n 'how many americans were affected by an oud related to non-medical  use of prescription pain relievers in 2014?',\n 'some patients on lot who suffer from chronic pain and co-occurring oud, depression, and/or personality disorders may do what?',\n 'how do exercise and  psychological therapies help reduce pain intensity and disability?',\n 'based on the study, which factors influence the rates of opioid-use continuation in veterans?',\n 'among patients on ot, what was significantly higher among patients with a history of ptsd as compared to patients with other (or no) mental  health diagnoses?',\n 'what accompanied the 2015 national drug control strategy?',\n 'what are recommended as alternatives to opioid therapy?',\n 'who had far less risk of developing oud or overdose compared to subjects 18-29 years old?',\n 'what timeframe is recommended if prescribing opioid therapy for patients with chronic pain?',\n 'why does the osi use veterans health administration (vha’s) electronic health record?',\n 'when to stop faster tapering?',\n 'what were the changes in the sales of prescription opioids in the u.s. from 1999 and 2014, according to cdc?',\n 'what are the odds of a lifetime suicide attempt in those with bipolar disorder compared to those with no bipolar disorder?',\n 'what to do for patients who are currently prescribed doses over 90 mg morphine equivalent daily dose?',\n 'what to ensure before initiating an opioid taper?',\n 'what has been an effective risk mitigation strategy for reducing high-risk behaviors and infectious disease transmission among injection drug users?',\n 'what is needed when there is progressive numbness or weakness?',\n 'how many americans suffer from some form of chronic pain?',\n 'what are used throughout the country for detection of multi-sourcing of controlled substances?',\n 'what to do if there is use of opioids to modulate emotions or an untreated or undertreated psychiatric disorder?',\n 'what increases the risk of overdose and overdose death?',\n 'what to do immediately after discontinuing ot?',\n 'which treatment for chronic pain may have benefits in treating depression, ptsd, and in reducing suicide risk?',\n 'when did va deploy the opioid safety initiative requirements to all veterans integrated service networks?',\n 'compared to patients ≥65 years old, patients 31-40 years old carried how many times the odds of oud  and overdose?',\n 'who will have other adverse events?',\n 'when we may not see withdrawal symptoms?',\n 'what should not be used for treatment of acute pain?',\n 'who mandated training on the appropriate and effective prescribing of opioid medications to all employees who prescribe controlled substances as part of their federal responsibilities and duties?',\n 'when can this guideline be used?',\n 'medication assisted treatment is recommended for what?',\n 'what is necessary to more accurately determine how long it takes for oud to occur?',\n 'what to discuss before starting the treatment?',\n 'on which kind of opioids the use of the distribution of naloxone does not have established clinical efficacy?',\n 'which concerns need to be addressed at the time of opioid tapering?',\n 'why may primary care providers require more time with patients?',\n 'why has returning unused opioid medications been explored as a strategy to reduce the amount of opioids in  the community?',\n 'how much does the risk increase at a range of 50 to <100 mg medd compared to risk at <20 mg medd?',\n 'what was the first opioid used by most of the people entering sud treatment for heroin use in the 1960s?',\n 'what can be difficult to distinguish from the underlying mechanism of illness?',\n 'what was the purpose of the oend program?',\n 'in a study of civilian patients who had been on opioids for at least 90 days, how many remained on opioids through the 4.8 year follow-up period?',\n 'what should be considered when a closer follow-up is needed?',\n 'which symptoms of withdrawal may take longer?',\n 'which became synonymous with lot in the 1990s and the first decade of the 2000s?',\n 'which opioid/opioid formulation is preferred over the others?',\n 'what does the updated cpg include?',\n 'how can it guide a patient encounter?',\n 'what to do if prior medical records are available for review?',\n 'what does oend refer to?',\n 'who can use this guideline?',\n 'what to do once opioid therapy is initiated?',\n 'what treatment modality may result in worsening of the underlying headache condition in patients with migraine headaches, tension-type headaches, occipital neuralgia, or myofascial pain?',\n 'what to provide to patients at increased risk of overdose?',\n 'what is the aim of the cdc guideline for prescribing opioids for chronic pain?',\n 'what can be used to convey openness to discuss any future concerns?',\n 'for patients at risk for overdose, what should be done?',\n 'why exercise and psychological therapies are preferred over lot?',\n 'what to do if there is a concern for diversion?',\n 'what was mandated by the presidential memorandum of october 2015?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on month 1, what dose should be taken on month three of the slower opioid tapering?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on week 1, what dose should be taken on week five of the faster opioid tapering?',\n 'what does va/dod cpgs encourage clinicians to do?',\n 'why exercise and psychological therapies should be offered to all patients with chronic pain including  those currently receiving lot?',\n 'how to determine the situations where the benefits of lot clearly outweigh the risks?',\n 'what is recommended for patients who are currently prescribed doses over 90 mg morphine equivalent daily dose?',\n 'compared to whom, patients 31-40 years old carried 5 times the odds of oud and overdose?',\n 'the veteran undergoing slow tapering should be involved in what?',\n 'what to do when veteran strongly resists reduction?',\n 'what are some examples of social and psychological consequences on account of chronic pain?',\n 'what was the state of long-term safety or efficacy data when ot for chronic non-terminal pain became a mainstay of therapy?',\n 'what is a good predictor of overdose death?',\n 'what may be considered after stopping faster tapering after week 7?',\n 'if the initial goal is determined to be a dose reduction, what may indicate that complete discontinuation is more suitable?',\n 'how often the prescription drug monitoring program data need to be reviewed?',\n 'name two initiatives that are aimed at improving the safe use of opioids? ',\n 'which pain could be mechanical or chemical/inflammatory in nature?',\n 'why can benzodiazepines be challenging to discontinue once initiated?',\n 'what was coupled with the newly cautious approach to lot?',\n 'what is recommended as opioid dosage and risk increase?',\n 'what to do if the patient is prescribed opioid dose>90 mg medd?',\n 'what is the state of research on the effectiveness of lot for non-end-of-life pain?',\n 'what to be aware of during follow-ups?',\n 'what to do if a patient is not medically or psychiatrically unstable?',\n 'who did carry 5 times the odds of oud and overdose compared to patients ≥65 years old?',\n 'what is included in the discussion?',\n 'what to do if there is no evidence of diversion?',\n 'what is moral injury?',\n 'what is not static?',\n 'when must vha providers follow vha policy regarding education and signature informed consent?',\n 'what is an ineffective treatment modality for patients with occipital neuralgia?',\n 'what should be done for patients for whom lot is initiated?',\n 'what to do if the factors that increase risks of ot are present?',\n 'what does preclude the safe use of self-administered lot?',\n 'what should all patients in the healthcare system be offered?',\n 'the combination of zolpidem and opioids increases what?',\n 'what is not as strong as the evidence for harm associated with the combination of  opioids and benzodiazepines?',\n 'which delivery mechanism has no evidence of benefit ove traditional opioid delivery systems in patients with chronic pain? ',\n 'what was the amount of risk of developing oud or overdose in patients ≥70 years old compared to subjects 18-29 years old?',\n 'when is it recommended to evaluate benefits of continued opioid therapy and risk for opioid-related adverse events?',\n 'for whom ongoing risk mitigation strategies are recommended?',\n 'who published the national pain strategy?',\n 'if take-home opioids are prescribed, why is it recommended to have opioid therapy reassessment no later than 3-5 days?',\n 'what is the estimation of the lifetime prevalence for severe symptoms of oud among patients receiving long-term opioid therapy?',\n 'how much did the rate of heroin overdose deaths increase between 2000 and 2013?',\n 'as found from a survey of patients prescribed opioids for chronic non-cancer pain and their family members, how many patients reported that they used the medication for fun or to get high?',\n 'what is recommended when risks of long-term opioid therapy outweigh benefits?',\n 'how long does it take for late withdrawal symptoms to appear?',\n 'what are the examples of dual-mechanism opioids?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on month 1, what dose should be taken on month two of the slower opioid tapering?',\n 'how are the standards of care determined?',\n 'how to choose between psychological and physical therapies as a first-try?',\n 'what to do when there is no improvement in function?',\n 'why is future research needed to optimize care for chronic-pain patients with and without cannabis use?',\n 'which tapers may be required in certain instances like drug diversion?',\n 'as found from a survey of patients prescribed opioids for chronic non-cancer pain and their family members, how many patients reported that they thought they were addicted/dependent on opioid pain medication?',\n 'patients receiving opioid analgesics who do not meet dsm-5 criteria for oud may benefit from what?',\n 'which factors were considered for the framework for recommendations in this cpg?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day ten of the rapid opioid tapering?',\n 'what is the effect of concurrent use of benzodiazepines with prescription opioids?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day two of the rapid opioid tapering?',\n 'who are recommended to be offered medication assisted treatment? ',\n 'what to do if referral/consultation for evaluation and treatment is not indicated?',\n 'what is accompanied by an increased rate of the human immunodeficiency virus (hiv) and hepatitis infection?',\n 'is there any absolutely safe dose of opioids?',\n 'patients on long-acting opioids within the facilities providing more follow-up after new prescriptions  were associated with what?',\n 'what kind of evidence is there to support the use of otas and udt?',\n 'how much to take from days 21 to 30, when using morphine sr 15 mg tablets?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month five of the slowest opioid tapering?',\n 'what to do if an sud is identified?',\n 'what does the patient-centered assessment incorporate?',\n 'how should the guideline not be interpreted as?',\n 'is there any study on the outcome of population-based rates of opioid overdose mortality by opioid dose, without the use of a presupposed threshold?',\n 'what does this guideline not cover?',\n 'what does a gradual taper rate allow?',\n 'for whom ongoing risk mitigation strategies, assessment for opioid use disorder, and consideration for tapering when risks exceed benefits are recommended?',\n 'what does place patients at elevated risk for opioid overdose?',\n 'for whom consideration for tapering when risks exceed benefits is recommended?',\n 'what is the recommended dose if blood pressure <90/60 mmhg while administering clonidine for autonomic symptoms?',\n 'in a study of veterans with chronic pain who had been on opioids for at least 90 days, how many continued to use opioids one year later?',\n 'what to do when dosage indicates high risk of adverse events?',\n 'when must special attention be given to ensure that the veteran does not feel abandoned?',\n 'what is sugested when opioids are used for acute pain?',\n 'which mental health comorbidities can worsen with opioid therapy?',\n 'when is it recommended to taper to reduced dose or to discontinuation of long-term opioid therapy?',\n 'what are some examples of mental health disorders?',\n 'what are the limitation of this cpg?',\n 'follow-up for tapering is recommended to be what?',\n 'what to do if the patient demonstrates signs or symptoms of sud?',\n 'what was the amount of risk of developing oud or overdose in patients 30-39  years old compared to subjects 18-29 years old?',\n 'what does va/dod suicide cpg refer to?',\n 'what does the 2017 version of the va/dod ot cpg provide?',\n 'what is the stance regarding the concurrent use of benzodiazepines and opioids?',\n 'what should be included in the risk mitigation strategies and their frequency?',\n 'what to do if a  decision is made to initiate lot?',\n 'what should be avoided?',\n 'given the relevance of all four domains in grading recommendations, what did the work group encounter?',\n 'tapering the opioid analgesic without providing oud treatment may increase the risk of what?',\n 'what does udt refer to?',\n 'who were at an increased risk of death from drug overdose?',\n 'in 2010, what was the focus of national drug control strategy?',\n 'where can more information be found on the patient guide?',\n 'how is pain recognized by the biopsychosocial model of pain?',\n 'who may threaten suicide when providers recommend discontinuation of opioids?',\n 'when should an assessment of current suicide risk be made?',\n 'what is represented by chronic pain conditions?',\n 'for whom particular caution should be used when considering initiating benzodiazepines due to the difficulty of tapering or discontinuing benzodiazepines?',\n 'what was significantly associated with suicide attempts for the chronic use of short-acting and long-acting opioids?',\n 'what can be utilized to assist with managing the withdrawal symptoms?',\n 'what warranted a cautious approach to lot prioritizing safety?',\n 'community-based needle exchange programs have been shown to do what?',\n 'what is an example of the threat to rural communities from non-prescription opioid use and the potential benefits of needle exchange programs for use as a risk mitigation strategy?',\n 'what may be experienced by the patients with chronic pain?',\n 'where can more information on bipolar disorder be found?',\n 'for which patients the first recommendation should be for medication assisted treatment (mat) for oud?',\n 'which factors may indicate the need for more frequent follow-up?',\n 'on what kind of evidence should the providers who suspect diversion base treatment plans?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month seven of the slowest opioid tapering?',\n 'who may have decompensation during the taper?',\n 'which pain can lead to well-localized nociceptive mechanism pain?',\n 'what is associated with prescribed opioid dose?',\n 'why is continuing lot not recommended to “prevent suicide” in someone with chronic pain?',\n 'how frequently should the harms versus benefits be re-evaluated according to the cdc guideline?',\n 'what must be factored into clinical decision making on a case-by-case basis?',\n 'what is an ineffective treatment modality for patients with tension-type headaches?',\n 'when may consultation with a pain specialist, psychiatrist, or sud specialist be warranted?',\n 'in the literature review conducted for this cpg, are there any study evaluating the effectiveness of lot for outcomes lasting longer than 16 weeks?',\n 'what is the aim of most abuse deterrent formulations?',\n 'who are more likely to attempt suicide?',\n 'what are the alternative treatment options for autonomic symptoms?',\n 'what is not an absolute contraindication to lot?',\n 'what is the estimation of the lifetime prevalence for mild symptoms of oud among patients receiving long-term opioid therapy?',\n 'who should be offered medication-assisted treatment?',\n 'what to do if adding ot to comprehensive pain therapy is not indicated at this time?',\n 'on what to follow-up with the veteran?',\n 'what can be challenging to discontinue due to symptoms related to benzodiazepine dependence, exacerbations of ptsd, and/or anxiety?',\n 'in response to the recognition of pain and its management as a public health problem in 2011, what was investigated and reported by the national academy of medicine?',\n '5% opioid reduction of morphine sr 90 mg q8h = 270 medd during the first month in the slowest taper consists of what?',\n 'where can we find information on the management of substance use disorders?',\n 'most commonly, tapering involves dose reduction of how much every 4 weeks?',\n 'how much opioid to reduce in the rapid taper?',\n 'which specific safety precautions should all clinicians be aware of regarding transdermal fentanyl?',\n 'where to follow up with the veteran during the slower taper?',\n 'what to do if there is no high risk or dangerous behavior?',\n 'how was the interagency pain research coordinating committee created?',\n 'since the release of the clinical practice guideline, what has been growingly recognized?',\n 'what does help mitigate the risk of suicide among patients on lot?',\n 'who are the targeted individuals for the cdc guideline for prescribing opioids for chronic pain?',\n 'what is the format of the ideal approach to communicate between the  sud and pain management providers when a patient is referred for  sud treatment or is engaged in ongoing treatment?',\n 'when to administer naloxone?',\n 'what is recommended for patients less than 30 years of age currently on long-term opioid therapy?',\n 'what is the aim of the pain treatment in the biomedical model of pain care?',\n 'how can patients examine the guideline?',\n 'what to do if there are no factors requiring immediate attention?',\n 'if prescribing opioids, what is the recommended dose?',\n 'what to prescribe to patients at increased risk of overdose?',\n 'what can facilitate clinical risk assessment and adherence to risk mitigation?',\n 'what kind of increase has there been in the absolute number of deaths associated with the use of opioids between 2013 and 2014 alone?',\n 'which withdrawal symptoms in patients with chronic pain may improve over time?',\n 'what is associated with suicide risk among veterans receiving ot for cncp?',\n 'what can be signalled by frequent requests for atypically large quantities required to control pain?',\n 'which system is used by the cdc guideline to assign a  grade for the strength for each recommendation? ',\n 'what to do if there is an increase in patient distress?',\n 'which tapers may be required in certain instances like drug diversion, illegal activities, or situations where the risks of continuing the opioid outweigh the risks of a rapid taper?',\n 'what is otas?',\n 'who supports the distribution of naloxone for the reversal?',\n 'what are some examples of concerns that may negatively impact taper?',\n 'when to re-evaluate the risks and benefits of continuing opioid therapy?',\n 'slower, more gradual tapers can be completed over several months to years based on what?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on month 1, what dose should be taken on month five of the slower opioid tapering?',\n 'when to stop slower tapering?',\n 'which model was adopted after the biomedical model of pain care?',\n 'what could also by itself be a sign of diversion?',\n 'how many studies examined age as a predictor of oud,  respiratory/cns depression, and/or overdose?',\n 'what does a comprehensive pain assessment include?',\n 'what does implementing more extensive risk mitigation strategies entail?',\n 'what are the risks associated with tapering?',\n 'when was cara enacted?',\n 'when reducing 5% of morphine sr 90 mg q8h = 270 medd, what dose should be taken on month eight of the slowest opioid tapering?',\n 'which treatments are preferred over lot?',\n 'every healthcare professional making use of these guidelines is responsible for what?',\n 'in comparison to patients in the 20-44 age  group, patients in the 45-64 year age group were significantly less likely to have what?',\n 'why is an empathetic and non-judgmental approach highly recommended for communication with a patient?',\n 'exacerbation of severe ptsd symptoms may result from what?',\n 'what is recommended at least every 3 months?',\n 'which taper can cause withdrawal effects?',\n 'what is the treatment option for abdominal cramping?',\n 'what is chemical coping?',\n 'what to do during a follow-up with a patient?',\n 'who are at risk for oud and overdose?',\n 'what is the va/dod guideline for guidelines?',\n 'what should not be prescribed concurrently when possible?',\n 'what kind of dose of opioids do not exist?',\n 'which four domains were considered to make the recommendations?',\n 'what should be done before the opioids are prescribed?',\n 'when was the clinical practice guideline for management of opioid therapy for chronic pain published?',\n 'what is recommended upon initiation of long-term opioid  therapy?',\n 'how long does it take to resolve early symptoms?',\n 'who to include in the discussion?',\n 'what percentage of people entering sud treatment for heroin use started using heroin as their first opioid in the 1960s?',\n 'is there any evidence that suggests an association with prescribed opioid dose and suicide risk among veterans receiving ot for cncp?',\n 'how much has the absolute number of deaths associated with the use of opioids increased since 2000?',\n 'what is the expected outcome of successful implementation of this guideline?',\n 'when tapering is being considered, which section in the guideline can be used to assist in the development of a framework for guiding an individualized, informed discussion?',\n 'who is sponsoring the training and related management support?',\n 'what is a national public health problem as outlined in the 2011 study by the national academy of medicine?',\n 'what to do if there is high risk or dangerous behaviors?',\n 'if patients are prescribed both long-acting and short-acting opioids, the decision about which formulation to be tapered first should be individualized based on what?',\n 'what to do if the treatments are effective in managing pain and optimizing function?',\n 'at what dose do risks for opioid use disorder begin?',\n 'what does the va/dod guideline for guidelines provide?',\n 'when was a recommendation to update the 2010 ot cpg initiated?',\n 'who has the highest adjusted odds ratio (aor) for drug  overdose?',\n 'is there any evidence of the comparative efficacy of tramadol versus another opioid or a non-opioid comparison such  as non-steroidal anti-inflammatory drugs (nsaids) or acetaminophen?',\n 'how to minimize withdrawal effects in patients caused by rapid tapers?',\n 'what are some examples of severe unmanageable adverse effects?',\n 'how to provide methadone for oud therapy?',\n 'what does require reevaluation and discussion of risks and benefits with patients?',\n 'what should be weighed heavily in the risk benefit calculus for lot?',\n 'when to consider tapering opioids to lower doses?',\n 'what are at increased risk of abnormalities and  addiction when exposed to substance use early in life?',\n 'what to do when there is concomitant use of medications that increase risk?',\n 'name a sleep disorder.',\n 'what is associated with little evidence for sustained analgesic efficacy but a substantial increase in risk for oud?',\n 'what are examples of non-adherence to the treatment plan or unsafe behaviors?',\n 'what is the purpose of patient-centered care?',\n 'what are the signs of/risk factors for infection?',\n 'what to do when there is an overdose event involving opioids?',\n 'what is necessary to more accurately determine how long it takes for oud to occur and whether the  nature of the pain is one of the factors that can influence either of this phenomena?',\n 'what to assess during a follow-up with a patient?',\n 'what is samhsa?',\n 'where to follow up with the veteran during the rapid taper?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on month 1, what dose should be taken on month four of the slower opioid tapering?',\n 'what are included in the underlying concepts of the biopsychosocial model of pain?',\n 'what were the top five most common medications collected in a 2013 medication take back event in a michigan community?',\n 'which topics are covered in the cdc guideline for prescribing opioids for chronic pain?',\n 'is there any evidence that certain chronic pain conditions represent an independent risk factor for suicide?',\n 'whom to prescribe naloxone?',\n 'in response to the recognition of pain and its management as a public health problem in 2011, who investigated and reported on the state of pain research, treatment, and  education in the u.s.?',\n 'who may benefit from an alternative management strategy?',\n 'what are the components of the oend program?',\n 'what is phi?',\n 'what to do if the patient is not willing to engage in a comprehensive pain care plan?',\n 'clinicians should continue the slowest taper based on what?',\n 'what are some examples of semi-synthetic opioids?',\n 'who should be offered mat?',\n 'what is included in the ongoing ot prescribing practice?',\n 'what does increase the risk for serious prescription opioid-related toxicity or overdose across opioid dosages in patients?',\n 'what was the tasks of interagency pain research coordinating committee?',\n 'what to implement and optimize for patients who are in chronic pain and have not been on daily ot for pain for more than 3 months?',\n 'according to cdc, what needs to be checked at least quarterly?',\n 'what is cncp?',\n 'what to do if the patient is not prepared to accept responsibilities or the provider is not prepared to implement risk mitigation strategies?',\n 'who may need to be included in the follow-up plan?',\n 'what should be done when a patient is referred for  sud treatment or is engaged in on-going treatment?',\n 'what may change the risk/benefit calculus for lot?',\n 'what to do if a patient is with chronic pain and has not been on daily ot for pain for more than 3 months?',\n 'when is it important to assess suicide risk?',\n 'when was the interagency pain research coordinating committee created?',\n 'which factors can describe and characterize pain as a symptom?',\n 'what are psychological factors?',\n 'who are at a higher risk of opioid misuse?',\n 'why should abrupt discontinuation of benzodiazepines be avoided?',\n 'what can be caused by fentanyl analogs that may be used to create counterfeit opioid analgesic pills?',\n 'the ultimate judgement regarding a particular clinical procedure or treatment course must be made in light of what?',\n 'which patients may be at risk?',\n 'how should risk mitigation for lot begin before the opioids are prescribed?',\n 'who developed the guidelines?',\n 'what are differences in the recommendations between the cdc guideline and the cpg?',\n 'what to do at each step in the taper?',\n 'which techniques to use to acknowledge the veteran’s fears about tapering?',\n 'what does this cpg not do?',\n 'who are at an increased risks of acute ot extending into lot?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day three of the rapid opioid tapering?',\n 'why did vha issue a policy requiring  standardized education and signature informed consent for all patients receiving lot for non-cancer  pain? ',\n 'what is recommended if prescribing opioid therapy for patients with chronic pain?',\n 'what was the aim of the national pain strategy?',\n 'how to determine whether patient risks outweigh benefits?',\n 'what is critical due to the false positive and negative rates associated with udts?',\n 'when may a consultation with an allergist be helpful?',\n 'who had higher rates  of oud?',\n 'the 2015 outbreak of hiv/hepatitis in rural indiana and subsequent successful implementation of a needle exchange program is an example of what?',\n 'what are significantly less likely in patients in the 45-64 and ≥65 age groups than 20-44 year olds?',\n 'why is ongoing assessment of suicide risk important whether one is initiating, maintaining,  or terminating lot?',\n 'depending on which factors monitoring standards with administration of ot for acute pain vary?',\n 'which represent an independent risk factor for suicide?',\n 'to what the prevalence of oud in patients with cncp is related?',\n 'what risk is recommended to be evaluated at least every 3 months?',\n 'when to follow up with the veteran during the slower taper?',\n 'what can cause moral injury?',\n 'since when has there been a significant increment of opioid prescriptions during pain visits?',\n 'what do udts do when used appropriately?',\n 'define chronic pain according to the va/dod cpg.',\n 'what should be the duration and dosage when initiatiing opioid thrapy? ',\n 'a discussion should occur between the veteran, family members/caregivers, and the provider prior to what?',\n 'what to do if the patient is willing to engage in sud therapy?',\n 'what information should be discussed with patients at initiation of ot and continuously thereafter?',\n 'who must make the ultimate judgement regarding a particular clinical procedure or treatment course?',\n 'what is needed when there are signs of/risk factors for infection?',\n 'being developed by a panel of multidisciplinary experts, what does the guideline do?',\n 'there may be some variation in what?',\n 'which opioid risk mitigation strategies should be incorporateed into opioid prescribing for acute pain?',\n 'what are some examples of absolute contraindications to initiating opioid therapy for chronic pain?',\n 'what is the stance regarding opioid doses over 90 mg morphine equivalent daily dose for treating chronic pain?',\n 'since when has there been growing recognition of opioid use disorder in america, including among america’s veterans?',\n 'what should be considered for non-opioid pharmacologic agents?',\n 'what is recommended for mild-to-moderate acute pain?',\n 'for whom should the slowest taper be considered?',\n 'what is the relationship between harms and benefits for the concurrent use of benzodiazepines and lot?',\n 'what to do when there is no pain reduction?',\n 'when should risk mitigation for lot occur?',\n 'as found from a survey of patients prescribed opioids for chronic non-cancer pain and their family members, how many patients reported that they used the medication to relieve day-to-day stress?',\n 'among patients  being treated by the vha system that received opioids, a history of depression was  significantly associated with what?',\n 'when reducing 16% of morphine sr 90 mg q8h = 270 medd on month 1, what dose should be taken on month seven of the slower opioid tapering?',\n 'what are the treatment options for myalgias?',\n 'how may lot affect patients with migraine headaches, tension-type headaches, occipital neuralgia, or myofascial pain?',\n 'where does ot have a limited role?',\n 'what is the role of ot in the treatment of severe acute pain, post-operative pain, and end-of-life pain?',\n 'how many people died between 1999 and 2015 from overdoses related to prescription opioids?',\n 'what may not reliably detect synthetic or semi-synthetic opioids?',\n 'what is an example of non-adherence to opioid prescription?',\n 'availability of accurate and timely confirmatory testing (e.g., gas chromatography-mass spectrometry  [gcms]) is critical due to what?',\n 'which conditions significantly increase the risk of adverse outcomes from lot?',\n 'where can the guidance on management of sud be found?',\n 'what kind of approach is highly recommended for communication with a patient?',\n 'what to use to educate the veteran?',\n 'compared to whom, patients 18-30 years old carried 11 times the odds of oud  and overdose?',\n 'what to do if an sud is not identified and there is use of opioids to modulate emotions or an untreated or undertreated psychiatric disorder?',\n 'what is an example of opioid medications?',\n 'intensification of monitoring helps with what?',\n 'which tapers may be required in certain instances like illegal activities?',\n 'what to inform patient regarding progression from acute to long-term ot?',\n 'what may increase the risk of overdose and other adverse events in patients with chronic pain and oud?',\n 'what is not an absolute contraindication to lot?',\n 'when did a more cautious approach to ot for chronic non-terminal pain emerge?',\n 'who did carry 11 times the odds of oud and overdose compared to patients ≥65 years old?',\n 'when reducing 33% of morphine sr 90 mg q8h = 270 medd on day 1, what dose should be taken on day eight of the rapid opioid tapering?',\n 'how to make sure that the veteran does not feel abandoned when a decision is made to taper?',\n 'how did the 2015 national drug control strategy and an accompanying presidential memorandum encourage the improvement of health and safety using evidence-based methods regarding sud treatments?',\n 'it is inadvisable to prescribe opioids to which patients?',\n 'what is the stance regarding long-term opioid therapy for patients less than 30 years of age secondary to higher risk of opioid use disorder and overdose?',\n 'what is the primary focus of the cara?',\n 'what is the aim of cara?',\n 'what is the updated cpg intended for?',\n 'what needs to be better determined by researchers?',\n 'what is required when considering opioid therapy beyond 90 days?',\n 'what can happen with the combined use of antidepressants and opioids in patients who do not have depression?',\n 'in which areas the national pain strategy made recommendations?',\n 'which opioid has unique pharmacodynamic properties that can prolong the qtc interval and precipitate torsades de pointes, a dangerous or fatal cardiac arrhythmia?']"},"metadata":{}}]},{"cell_type":"code","source":"import torch\ntorch.cuda.empty_cache()\nfrom transformers import pipeline","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:35:59.701802Z","iopub.execute_input":"2023-01-31T01:35:59.702368Z","iopub.status.idle":"2023-01-31T01:36:10.402955Z","shell.execute_reply.started":"2023-01-31T01:35:59.702319Z","shell.execute_reply":"2023-01-31T01:36:10.401864Z"},"trusted":true},"execution_count":4,"outputs":[]},{"cell_type":"code","source":"from transformers import AutoTokenizer, AutoModelForSeq2SeqLM\nmodel = AutoModelForSeq2SeqLM.from_pretrained(f\"Helsinki-NLP/opus-mt-{language1}-jap\")\ntokenizer = AutoTokenizer.from_pretrained(f\"Helsinki-NLP/opus-mt-{language1}-jap\")","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:36:10.404238Z","iopub.execute_input":"2023-01-31T01:36:10.405748Z","iopub.status.idle":"2023-01-31T01:36:27.189822Z","shell.execute_reply.started":"2023-01-31T01:36:10.405714Z","shell.execute_reply":"2023-01-31T01:36:27.188710Z"},"trusted":true},"execution_count":5,"outputs":[{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/1.35k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"83068cb840394c24810efb4e00b40f0d"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/261M [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"3e06d671f2c442fc83caca385f7415a3"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/43.0 [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"f43d1089743a4d2982e388d0141bf31a"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/497k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"3a50edfa1fd243e49754f4dac3c259ca"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/998k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"01299ec6ef0040dfad4edacbb91a3bcd"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/1.57M [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"83256406faf64d06bd6f896f77cf7b26"}},"metadata":{}}]},{"cell_type":"code","source":"model.to('cuda:0')\npipe = pipeline(\"translation\", model=model, tokenizer=tokenizer, device = 0)","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:36:27.191680Z","iopub.execute_input":"2023-01-31T01:36:27.192129Z","iopub.status.idle":"2023-01-31T01:36:32.857326Z","shell.execute_reply.started":"2023-01-31T01:36:27.192077Z","shell.execute_reply":"2023-01-31T01:36:32.856392Z"},"trusted":true},"execution_count":6,"outputs":[]},{"cell_type":"code","source":"#COVID\nfrom transformers import pipeline\nfrom tqdm import tqdm\n\n#FIRST TRANSLATION\nfirst = []\nfor question in tqdm(questions):\n    translated_str = pipe(question)[0]['translation_text']\n    first.append(translated_str)","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:36:32.858750Z","iopub.execute_input":"2023-01-31T01:36:32.859131Z","iopub.status.idle":"2023-01-31T01:41:17.193455Z","shell.execute_reply.started":"2023-01-31T01:36:32.859091Z","shell.execute_reply":"2023-01-31T01:41:17.192437Z"},"trusted":true},"execution_count":7,"outputs":[{"name":"stderr","text":"  1%|          | 10/877 [00:04<03:36,  4.01it/s]/opt/conda/lib/python3.7/site-packages/transformers/pipelines/base.py:1015: UserWarning: You seem to be using the pipelines sequentially on GPU. In order to maximize efficiency please use a dataset\n  UserWarning,\n100%|██████████| 877/877 [04:44<00:00,  3.08it/s]\n","output_type":"stream"}]},{"cell_type":"code","source":"torch.cuda.empty_cache()","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:41:17.194963Z","iopub.execute_input":"2023-01-31T01:41:17.195689Z","iopub.status.idle":"2023-01-31T01:41:17.208813Z","shell.execute_reply.started":"2023-01-31T01:41:17.195646Z","shell.execute_reply":"2023-01-31T01:41:17.207874Z"},"trusted":true},"execution_count":8,"outputs":[]},{"cell_type":"code","source":"model = AutoModelForSeq2SeqLM.from_pretrained(f\"Helsinki-NLP/opus-mt-ja-{language1}\")\ntokenizer = AutoTokenizer.from_pretrained(f\"Helsinki-NLP/opus-mt-ja-{language1}\")","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:41:17.211027Z","iopub.execute_input":"2023-01-31T01:41:17.211501Z","iopub.status.idle":"2023-01-31T01:41:34.481317Z","shell.execute_reply.started":"2023-01-31T01:41:17.211461Z","shell.execute_reply":"2023-01-31T01:41:34.480282Z"},"trusted":true},"execution_count":9,"outputs":[{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/1.35k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"68f00480687846d5aba934c3e691772a"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/289M [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"a3ac6bf375134a1ca36696707362edeb"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/42.0 [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"f645779dd5634f95b34dcc0f34d377e6"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/764k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"0ee32cfe55864dc2a36c4ad5e82a0669"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/783k [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"d2805941012e4a40afe556fd702b55c1"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":"Downloading:   0%|          | 0.00/1.43M [00:00<?, ?B/s]","application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"bc8147c6b2744cb38a7c181e86f82c76"}},"metadata":{}}]},{"cell_type":"code","source":"model.to('cuda:0')\npipe = pipeline(\"translation\", model=model, tokenizer=tokenizer, device = 0)","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:41:34.485055Z","iopub.execute_input":"2023-01-31T01:41:34.485474Z","iopub.status.idle":"2023-01-31T01:41:34.604330Z","shell.execute_reply.started":"2023-01-31T01:41:34.485434Z","shell.execute_reply":"2023-01-31T01:41:34.603304Z"},"trusted":true},"execution_count":10,"outputs":[]},{"cell_type":"code","source":"#COVID\n#SECOND TRANSLATION\nsecond = []\nfor question in tqdm(first):\n    translated_str = pipe(question)[0]['translation_text']\n    second.append(translated_str)","metadata":{"execution":{"iopub.status.busy":"2023-01-31T01:41:34.606099Z","iopub.execute_input":"2023-01-31T01:41:34.606505Z"},"trusted":true},"execution_count":null,"outputs":[{"name":"stderr","text":"  6%|▌         | 51/877 [00:11<03:31,  3.91it/s]","output_type":"stream"}]},{"cell_type":"code","source":"#COVID -- replace question in json then save\nfor i in range(len(objs)):\n    objs[i][\"question\"] = second[i]\nwith open(\"cpgQA-{}-{}-{}-{}.json\".format(file,language1,language2,language1), 'w') as f:\n                f.write(json.dumps(objs, indent = 4) + \"\\n\")","metadata":{"trusted":true},"execution_count":null,"outputs":[]},{"cell_type":"code","source":"","metadata":{},"execution_count":null,"outputs":[]},{"cell_type":"code","source":"","metadata":{},"execution_count":null,"outputs":[]}]}